|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Minor therapeutic impact | | | | | | | | | | | |
|  |  | on N | | on M | | SPC | | Total | | upstaging | | downstaging | |
| Oral cavity | n=99 | 38 | (38,4) | 4 | (4,0) | 9 | (9,1) | 43 | (43,4) | 33 | (76,7) | 10 | (23,3) |
| Oropharynx | n=187 | 77 | (41,2) | 10 | (5,3) | 9 | (4,8) | 92 | (49,2) | 67 | (72,8) | 25 | (27,2) |
| Larynx | n=103 | 34 | (33,0) | 3 | (2,9) | 9 | (8,7) | 44 | (42,7) | 30 | (68,2) | 14 | (31,8) |
| Hypopharynx | n=88 | 33 | (37,5) | 5 | (5,7) | 8 | (9,1) | 42 | (47,7) | 35 | (83,3) | 7 | (16,7) |
| Total | n=477 | 182 | (38,2) | 22 | (4,6) | 35 | (7,3) | 221 | (46,3) | 165 | (74,7) | 56 | (25,3) |

Table S1 Type of minor therapeutic impact, by modifying lymph node status (N), metastatic status (M), or synchronous cancer discovery. The types of impact are differentiated into upstaging and downstaging. The percentages in brackets are given in relation to the total number of patients.